Program
mezigdomide
Also written as “CC-92480”, “Mezigdomide” and “Cohort B1 & B2: KTX-1001+Mezigdomide”.
Its studies are mostly in Multiple Myeloma · Kidney Failure, Chronic, led by 2 companies.
Drug pageMezigdomide: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 113 open or running | phase 3since Aug 25, 2022 | Dec 1, 2017 | Jan 10, 2027phase 3 · NCT05519085 |
| K36 Therapeutics | 11 open or running | phase 1since Dec 1, 2022 | Dec 1, 2022 | Dec 31, 2027phase 1 · NCT05651932 |
- Named in Bristol-Myers Squibb’s own pipeline as
mezigdomide
, phase 4, as of Oct 29, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of K36 Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 28, 2021Named mezigdomideINNProposed as its International Nonproprietary Name in WHO's List 125 · before, CC-92480
- Dec 1, 2022First study: phase 1 study in Multiple MyelomaFirst studyNCT05651932 · 165 planned · United States, Canada, France and more
Ahead
- Dec 31, 2027Primary completion: phase 1 study in Multiple MyelomaNCT05651932
TargetBeta
“A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and target…”NCIt, read by Claude
Other programs on CRBN
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 109 |
| pomalidomiderule | Bristol-Myers Squibb | phase 4 | 51 |
| golcadomide | Bristol-Myers Squibb | phase 3 | 11 |
| Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506 | Bristol-Myers Squibb | phase 1 | 1 |
| HRS-3738 | Jiangsu HengRui Medicine | phase 1 | 1 |
Studies
The one study K36 Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05651932Multiple Myeloma · United States, Canada, France and more | 1 | Recruiting | Dec 31, 2027 | 165 |
How it is read
Names in the registry
- “CC-92480”, 6 entries
- “Mezigdomide”, 4 entries
- “Cohort B1 & B2: KTX-1001+Mezigdomide”, 1 entry
- “mezigdomide”, 1 entry
- “[14C]-CC-92480”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 5 studies
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.